GoAI
Get started
Regent Pacific Group Limited logo

Regent Pacific Group Limited

0575.HK

HKSEHealthcareMedical - Pharmaceuticals

Open in GoAI

Latest quote

HK$0.89

−HK$0.01 · -1.11%

Aug 21, 1:37 PM HKT

0575.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Regent Pacific Group Limited is an investment holding company that primarily focuses on the healthcare and life sciences sectors. The company is involved in the research, development, and sale of pharmaceutical products, with a notable focus on treatments for urological disorders. It also invests in a portfolio of both listed and unlisted corporate entities.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
HK
CEO
Jamie Alexander Gibson
Listed since
May 19, 1997
Employees
17

Market position

52-week range

Current HK$0.89

Open
HK$0.89
Previous close
HK$0.90
Volume
20K
0.13× average
Average volume
154.34K
Average daily volume
Market cap
259.72M HKD
Beta
1.12
Market reference 1
50-day average
HK$0.9261
-3.90% below average
200-day average
HK$0.8587
+3.64% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
39.71M USD
P/E (TTM)
-6.24×
P/B (TTM)
-5×
P/S (TTM)
91.31×
EV / EBITDA
-9.26×
Earnings yield
-13.11%
Free cash flow yield
-12.02%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-115.70%
Operating margin
-1187.88%
Net margin
-1297.52%
Return on equity
70.93%
Return on assets
-824.98%
Return on invested capital
-754.58%

Financial health

Debt / equity
-0.59×
Current ratio
0.07×
Altman Z-score
-825.83
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3224%-9568%-22360%-35151%Gross margin, FY2021: 26.12%Gross margin, FY2022: -971.05%Gross margin, FY2023: -613.09%Gross margin, FY2024: -30.46%Gross margin, FY2025: -115.70%Operating margin, FY2021: -426.34%Operating margin, FY2022: -30697.37%Operating margin, FY2023: -7953.66%Operating margin, FY2024: -603.20%Operating margin, FY2025: -1187.88%Net margin, FY2021: -387.15%Net margin, FY2022: -31953.51%Net margin, FY2023: -6557.33%Net margin, FY2024: -623.37%Net margin, FY2025: -1297.52%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 26.12%. Gross margin FY2022 -971.05%. Gross margin FY2023 -613.09%. Gross margin FY2024 -30.46%. Gross margin FY2025 -115.70%. Operating margin FY2021 -426.34%. Operating margin FY2022 -30697.37%. Operating margin FY2023 -7953.66%. Operating margin FY2024 -603.20%. Operating margin FY2025 -1187.88%. Net margin FY2021 -387.15%. Net margin FY2022 -31953.51%. Net margin FY2023 -6557.33%. Net margin FY2024 -623.37%. Net margin FY2025 -1297.52%.

Income trends

Revenue

363K USD-49.51%

Operating income

−4.31M USD+0.58%

Net income

−4.71M USD-5.09%
Income trends across reported periods7.22M USD−8.65M USD−24.52M USD−40.4M USDRevenue, FY2021: 3.25M USDRevenue, FY2022: 114K USDRevenue, FY2023: 382K USDRevenue, FY2024: 719K USDRevenue, FY2025: 363K USDOperating income, FY2021: −13.87M USDOperating income, FY2022: −35M USDOperating income, FY2023: −30.38M USDOperating income, FY2024: −4.34M USDOperating income, FY2025: −4.31M USDNet income, FY2021: −12.6M USDNet income, FY2022: −36.43M USDNet income, FY2023: −25.05M USDNet income, FY2024: −4.48M USDNet income, FY2025: −4.71M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.25M USD. Revenue FY2022 114K USD. Revenue FY2023 382K USD. Revenue FY2024 719K USD. Revenue FY2025 363K USD. Operating income FY2021 −13.87M USD. Operating income FY2022 −35M USD. Operating income FY2023 −30.38M USD. Operating income FY2024 −4.34M USD. Operating income FY2025 −4.31M USD. Net income FY2021 −12.6M USD. Net income FY2022 −36.43M USD. Net income FY2023 −25.05M USD. Net income FY2024 −4.48M USD. Net income FY2025 −4.71M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue363K USD719K USD382K USD114K USD3.25M USD
Cost of goods sold783K USD938K USD2.72M USD2.98M USD2.4M USD
Gross profit−420K USD−219K USD−2.34M USD−1.11M USD850K USD
Research and development783K USD938K USD1.38M USD1.22M USD2.4M USD
Selling, general, and administrative389K USD565K USD703K USD863K USD927K USD
Operating expenses3.89M USD4.12M USD28.04M USD33.89M USD14.72M USD
Interest expense368.54K USD171K USD80K USD1.01M USD1.22M USD
Depreciation and amortization8K USD22.2M USD22.66M USD25.44M USD24.25M USD
Operating income−4.31M USD−4.34M USD−30.38M USD−35M USD−13.87M USD
Net income−4.71M USD−4.48M USD−25.05M USD−36.43M USD−12.6M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.06

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.29-0.28-0.86-1.43Q2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 0.171, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -0.992, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 30, 2022: actual -1.31, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 30, 2023: actual -1.06, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual -0.431, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual -0.439, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual -0.09, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual -0.063, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates27.47M17.58M7.69M-2.2MQ2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 25.42M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -155.95K HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 30, 2022: actual 102K HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 30, 2023: actual 788.07K HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 642.51K HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 1.63M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual 335.83K HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 5.25M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$26.00

2013 complete year+358.2% since 2005

Corporate action history

Dividend

Ex-dividend Feb 8, 2013

HK$0.0007

Annual

Dividend

Ex-dividend Jan 16, 2012

HK$0.0002

Annual

Dividend

Ex-dividend Jan 4, 2011

HK$0.0001

Semi-Annual

Dividend

Ex-dividend Jun 3, 2010

HK$0.0001

Special

Dividend

Ex-dividend Nov 14, 2005

HK$0.0003

Special

Dividend

Ex-dividend Aug 19, 2004

HK$0.0003

Special

0575.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 0575.HK

research.disclaimer